Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

King's Health Partners' Prostate Cancer Biobank (KHP PCaBB).

S R Saifuddin1, W Devlies2,3, A Santaolalla1

  • 1School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research, King's College London, London, UK.

BMC Cancer
|November 24, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling the uncertainty: Cytomorphometric parameters in oral exfoliated cells falter in precise age estimation.

Morphologie : bulletin de l'Association des anatomistes·2026
Same author

Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries.

ESMO real world data and digital oncology·2026
Same author

Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort.

ESMO real world data and digital oncology·2026
Same author

Robotic-assisted retroperitoneal lymph node dissection: defining selection parameters-a B-SAFE approach.

Journal of robotic surgery·2025
Same author

Enhancement of Cold Electron Emission in Europium Doped Zinc Oxide Rod: An Experimental Verification of Simulative Prediction.

Small (Weinheim an der Bergstrasse, Germany)·2025
Same author

Two-step transconjunctival approach for suprachoroidal haemorrhage prior to clot liquefaction.

Journal francais d'ophtalmologie·2025
Same journal

Leveraging data-driven risk-adapted surveillance strategies after disease progression in locally advanced rectal cancer.

BMC cancer·2026
Same journal

Routine biomarkers map response probability in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2 blockade.

BMC cancer·2026
Same journal

Beyond side effects: treatment-related adverse events are associated with improved survival outcomes in HCC patients on atezolizumab-bevacizumab therapy.

BMC cancer·2026
Same journal

Clinical outcomes of percutaneous cryoablation for pulmonary metastases of soft tissue and bone sarcomas under local anesthesia: a single-institution retrospective cohort study.

BMC cancer·2026
Same journal

Catastrophic health expenditure and its determinant factors among patients with cancer attending Wolaita Sodo University Comprehensive Specialized Hospital, South Ethiopia.

BMC cancer·2026
Same journal

Single-session agreement of ChatGPT and Gemini treatment recommendations with multidisciplinary tumor board decisions in thoracic oncology.

BMC cancer·2026
See all related articles
This summary is machine-generated.

The King

Area of Science:

  • Uro-oncology
  • Cancer Biobanking
  • Prostate Cancer Research

Background:

  • Prostate cancer is increasingly managed as a chronic disease, necessitating long-term patient data and biological samples for research.
  • The King's Health Partners Prostate Cancer Biobank (KHP PCaBB) was established to support research into prostate cancer.
  • Biobanks are crucial for collecting and preserving patient samples and data for translational research.

Purpose of the Study:

  • To establish and characterize the King's Health Partners Prostate Cancer Biobank (KHP PCaBB).
  • To assess the representativeness of the biobank cohort compared to the overall prostate cancer patient population.
  • To highlight the potential of the biobank as a resource for prostate cancer research, including treatment response and disease markers.

Main Methods:

Keywords:
BiobankClinical databaseData resource profileProstate cancerTissue repository

Related Experiment Videos

  • Prospective recruitment of prostate cancer patients from Urology or Oncology Departments at Guy's Hospital.
  • Collection of patient consent for biobanking, including blood, prostate tissue, and clinical/pathological data.
  • Audit of biobank data (2013-2015) to compare demographic and clinical characteristics of consented patients versus the total patient population.

Main Results:

  • Between 2013 and 2015, 549 (30.6%) of 1796 diagnosed prostate cancer patients consented to the KHP PCaBB.
  • The biobank collected 489 blood samples, 120 frozen prostate tissue samples, and 1064 formalin-fixed paraffin-embedded blocks.
  • The KHP PCaBB cohort is demographically representative of the total prostate cancer patient population, with no significant differences in ethnicity or socioeconomic status, though treatment types differed.

Conclusions:

  • The KHP PCaBB has successfully created a substantial and representative data and tissue repository for prostate cancer research.
  • The biobank reflects the demographic and clinical diversity of the prostate cancer patient population at King's Health Partners.
  • This resource is well-positioned to facilitate research into treatment variations and disease markers across different prostate cancer risk categories.